Delivery Order SPE2DB20D3101-SPE2DB25FRMG2
- Not listed
- The Defense Logistics Agency awarded a $21,976.95 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with a completion date of July 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, chronic rhinosinusitis with nasal...
- The Defense Logistics Agency awarded a $17,791.36 delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed-price, non-set-aside contract with a completion date of June 27, 2025, and performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe eczema, asthma, and chronic...
- The Defense Logistics Agency awarded a $40,995.34 delivery order to AmerisourceBergen Drug Corp on April 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This competitively awarded, non-set-aside contract specifies firm fixed pricing with an ultimate completion date of April 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $13,293.08. This firm fixed-price delivery order, which is effective through August 27, 2025, represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $11,573.00. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other...
- The Defense Logistics Agency awarded a $26,328.21 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $10,591.02. This is a firm fixed price delivery order with no set-aside designation, awarded competitively to the prime contractor. The order is to be completed by August 6, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a...
- The Defense Logistics Agency awarded a $17,929.57 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for Dupixent 200 mg/1.14 mL pen injectors. This is a firm fixed-price, non-set-aside delivery order with a completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat conditions including moderate-to-severe eczema, asthma, and chronic rhinosinusitis, making...
- The Defense Logistics Agency awarded a delivery order valued at $42,788.32 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 21, 2025, with completion expected by July 22, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic...
- The Defense Logistics Agency awarded a $11,417.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on August 19, 2025, with completion targeted for August 20, 2025. This firm fixed-price, competitively awarded delivery order was issued without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a prescription biologic medication primarily used to treat...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRMG2Delivery Order
The Defense Logistics Agency awarded a $27,552.50 delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of June 6, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily indicated for moderate-to-severe atopic dermatitis, eosinophilic esophagitis, asthma, and chronic rhinosinusitis with nasal polyps, making this procurement part of the Defense Health Agency's pharmaceutical supply chain for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen leverages this comprehensive global contract vehicle to supply a broad range of pharmaceuticals, biologics, vaccines, and medical supplies to support military healthcare programs worldwide. The company's demonstrated capability to fulfill federal medical procurement requirements through competitive awards positions it as a critical supplier within the Defense Health Agency's pharmaceutical distribution network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.6k | 6/5/25 |